Live birth following double-factor pre-implantation genetic diagnosis for both reciprocal translocation and alpha-thalassaemia by Lee, VCY et al.
Title
Live birth following double-factor pre-implantation genetic
diagnosis for both reciprocal translocation and alpha-
thalassaemia
Author(s) Lee, VCY; Chow, JFC; Lau, EYL; Yeung, WSB; Ng, EHY
Citation Hong Kong Medical Journal, 2014, v. 20 n. 3, p. 251-254
Issued Date 2014
URL http://hdl.handle.net/10722/219198
Rights Hong Kong Medical Journal. Copyright © Hong Kong Academyof Medicine Press.
251Hong Kong Med J  ⎥  Volume 20 Number 3  ⎥  June 2014  ⎥  www.hkmj.org
A B S T R A C T 
We report a live birth from a couple with two genetic 
diseases, namely: reciprocal translocation carrier and 
alpha-thalassaemia trait, following pre-implantation 
genetic diagnostic tests. This is the first case in Hong 
Kong in which the technique of using one blastomere 
biopsy for two diseases was established, using array 
comparative genomic hybridisation and polymerase 
chain reaction.
Live birth following double-factor  
pre-implantation genetic diagnosis for both 
reciprocal translocation and alpha-thalassaemia
Introduction
In this report, we present a couple who requested 
a double-factor pre-implantation genetic diagnosis 
(PGD) for both reciprocal translocation and alpha-
thalassaemia.
Case report
Our patient, aged 36 years, enjoyed good past health 
and attended the subfertility clinic for recurrent 
miscarriage (5 times within 8 years). She had four 
spontaneous conceptions between 1997 and 2004 
but all ended as first-trimester miscarriages. After 
2004, she suffered from secondary subfertility 
and conceived again in 2007 following ovarian 
stimulation and intrauterine insemination. The 
fifth pregnancy again ended with first-trimester 
miscarriage.
 She was subsequently referred to a clinical 
geneticist and found to be a carrier of a balanced 
reciprocal translocation 46,XX,t(2;10)(q33;q21.2). 
The husband had normal karyotypes and other 
relevant investigations for recurrent miscarriage were 
all negative. Both partners were alpha-thalassaemia 
trait carriers (South East Asia [SEA] type) as the 
genotype report revealed heterozygous alpha SEA 
type deletion. They were therefore referred to us for 
PGD.
 Baseline investigations showed early follicular 
follicle-stimulating hormone levels of 6.5 IU/L 
and an antral follicle count of 19. The couple was 
counselled about the procedure and risks of PGD. 
It was decided to biopsy two blastomeres, so as 
to perform polymerase chain reaction (PCR) for 
alpha-thalassaemia on one of them, and carry out 
Hong Kong Med J 2014;20:251–4
DOI: 10.12809/hkmj134087
Vivian CY Lee *, Judy FC Chow, Estella YL Lau, William SB Yeung, Ernest HY Ng
VCY Lee *, FHKAM (Obstetrics and Gynaecology)
JFC Chow, MPhil
EYL Lau, PhD
WSB Yeung, PhD
EHY Ng, MD
Department of Obstetrics and Gynaecology, The University of Hong Kong, 
Queen Mary Hospital, Pokfulam, Hong Kong
* Corresponding author: v200lee@hku.hk
fluorescent in-situ hybridisation (FISH) for the 
reciprocal translocation on the other. 
 The first cycle of in-vitro fertilisation (IVF) and 
intra-cytoplasmic sperm injection (ICSI) was carried 
out in November 2010. After 10 days of ovarian 
stimulation, 12 oocytes were retrieved and 11 were 
in metaphase II for ICSI. Ten were normally fertilised 
and seven day-3 embryos were available for embryo 
biopsy. Two embryos were subsequently shown to 
be normal for FISH signals and either normal or 
heterozygous for alpha-thalassaemia SEA deletion. 
On day 5, there was only one fair-quality embryo at 
the morula stage for transfer, but the patient failed to 
conceive in that cycle. 
 She underwent a second IVF/ICSI/PGD cycle 
in January 2012. After 11 days of ovarian stimulation, 
13 oocytes were retrieved. Twelve were fertilised, 
and eight day-3 embryos were available for embryo 
biopsy. One embryo was found to be balanced 
for the FISH signals and heterozygous for alpha-
thalassaemia SEA deletion. That embryo developed 
to a good-quality blastocyst of grade 5BB and was 
transferred. She was pregnant but refused prenatal 
invasive testing in the second trimester because of 
the risk of miscarriage. She delivered a baby boy in 
October 2012 and the cord blood analysis confirmed 
the diagnosis of alpha-thalassaemia-1 carrier status 
with a normal karyotype 46,XY. 
Pre-implantation genetic diagnosis process
Optimisation process (direct mutation detection 
and linkage analysis)
The Gap-PCR approach was used to amplify the 
alpha-SEA type deletion junction directly (Fig 1). 
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為平衡性轉位帶因者和甲型地中海貧血兩種遺傳
基因疾病作胚胎植入前遺傳學診斷而結果為活產
的病例報告
李芷茵、鄒鳳翔、劉綺蘭、楊樹標、吳鴻裕
本文報告一對患有平衡性轉位帶因者和甲型地中海貧血兩種遺傳基因
疾病的夫婦，作胚胎植入前遺傳學診斷而活產的病例。這是香港首宗
病例，我們亦發展了採用一個卵裂球活檢作兩種基因測試的技術（包
括陣列比較基因組雜交技術及聚合酶鏈反應）。
Briefly, the normal allele was amplified by primers 
Zdel-1 and Zdel-2 (317 bp), but not by Zdel-1 and 
Xdel-3, because they were too far apart. In the alpha 
SEA deletion, the binding site for Zdel-2 was deleted, 
and that for Zdel-1 and Xdel-3 were brought into 
close proximity producing a PCR product of 280 bp. 
Linkage analysis was performed with fluorescent-
labelled intragenic informative markers (16pTEL05 
and 16pTEL06) and linked short tandem repeats 
(STR) markers within 2Mb flanking the alpha-globin 
loci (D16S521 and D16S3395). The relative positions 
of primers and markers around the alpha SEA 
deletion are shown in Figure 1. Single cell protocols, 
using multiple displacement amplification (MDA) 
or SurePlex DNA amplification, have been validated 
using single lymphocytes from the couple. 
Embryo biopsy and pre-implantation genetic 
diagnosis
Two blastomeres were biopsied from each of the 
good-quality day-3 embryos. One blastomere 
underwent whole genome amplification (WGA) 
and PCR for PGD on the alpha-thalassaemia loci. 
The second blastomere was lysed for translocation 
detection by FISH.
 In the first PGD cycle, WGA was performed 
by the MDA method according to the protocol 
previously published.1 In the second cycle, SurePlex 
DNA amplification (BlueGnome) was adopted for 
WGA. One μL of WGA product was used for PCR 
in a final volume of 25 μL containing 1X PCR buffer 
with MgSO4, 0.2 mM dNTPs, and 1U FastStart Taq 
DNA polymerase (Roche). 0.5 μL of PCR product 
was separated by an ABI 3500 genetic analyser 
with a GeneScan 500ROX-size standard (Applied 
Biosystems) and analysed by GeneMapper (v4.1; 
Applied Biosystems). 
 The second blastomere underwent FISH 
with Vysis probes Tel 2p (green), CEP10 (aqua), 
and Tel 10q (orange). The signals were interpreted 
independently by two scientists.
Pre-implantation genetic diagnosis results
In the first PGD cycle, Gap-PCR and intragenic 
informative markers 16pTEL05 and 16pTEL06 
were used for PGD. All seven biopsied blastomeres 
resulted in a conclusive diagnosis. In the second 
cycle, the PGD protocol was modified in a few ways. 
Firstly, WGA was performed using the SurePlex 
DNA amplification system. Secondly, Gap-PCR 
primers Zdel-1 and Zdel-2 were omitted, since 
they were poorly amplified in SurePlex WGA DNA. 
Finally, two additional linked STR markers (D16S521 
and D16S3395) were used to improve the diagnosis 
rate. Linkages of these additional markers with 
the SEA deletion locus were established with the 
leftover WGA DNA from embryos obtained in the 
first cycle. All embryos that underwent PGD showed 
conclusive results. 
Validation of one-blastomere protocol for double 
factor pre-implantation genetic diagnosis
The leftover WGA DNA in the second cycle of 
PGD was used for array comparative genomic 
hybridisation (aCGH, 24Sure+, BlueGnome) for 
the detection of translocation. All samples showed 
conclusive result, which was consistent with those 
after FISH (Fig 2). 
Discussion
Our unit has offered PGD treatment for monogenetic 
diseases for more than 10 years, starting in 2000 
for alpha-thalassaemia. The FISH technique was 
then developed for translocation carriers and pre-
implantation genetic aneuploidy screening. In this 
case report, the couple described was the first to 
request PGD for both reciprocal translocation and 
alpha thalassaemia. The couple firstly attended our 
unit for PGD in 2009 and at that time the FISH 
technique was still routinely used for translocation. 
We decided to have two blastomeres biopsied, and 
undertook PCR on one (for alpha-thalassaemia) and 
FISH on the other (for reciprocal translocation). 
It is well-known that two-blastomere biopsy is 
more detrimental than one-blastomere biopsy on 
the implantation and pregnancy rate after embryo 
FIG 1.  Schematic diagram on the relative positions of Gap–polymerase chain 
reaction primers and microsatellite markers
Abbreviation: SEA = South East Asia type of alpha-thalassaemia trait
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FIG 2.  Array comparative genomic hybridisation result of (a) pre-implantation genetic diagnosis blastomeres; embryos 4, 6, 7, 8, 9, 10, and 13 showing 
abnormal signals which are concordant with the fluorescent in-situ hybridisation (FISH) result, and (b) the embryo 5 (normal) which is replaced and 
results in a singleton live birth. Such result is concordant with both the FISH result and the karyotype of cord blood (46,XY)
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transfer.2 Since 2008, there was emerging evidence 
regarding the use of array CGH in both translocation 
carriers and preimplantation aneuploidy screening.3-5 
Using aCGH, it could obtain information on all 
24 chromosomes to detect aneuploidy, which is 
common in early human embryos, other than in 
translocated genetic material.4 Recourse to WGA 
in aCGH allowed us to use a single blastomere for 
both diagnoses as the amplified products could 
also be used for PCR. We switched to using WGA 
with SurePlex. However, before we acquired the 
technique of aCGH for PGD of translocation in 
2012, the couple requested the second treatment 
cycle because of advancing maternal age. Therefore 
FISH was used again in the second PGD cycle for 
translocation, as in the first cycle.
 Later, we used the leftover WGA DNA 
from the second PGD cycle for translocation and 
aneuploidy detection, using aCGH 2 weeks after the 
PGD treatment cycles. All embryos with abnormal 
FISH signals showed abnormal aCGH results (Fig 
2a). The normal embryo showed a normal signal 
with no aneuploidy detected after aCGH, which was 
performed immediately after the delivery of the baby 
boy (Fig 2b). Karyotyping on cord blood of the baby 
confirmed our PGD and aCGH results. 
 So far, there have been three case reports 
from the same group of investigators on the use of 
double-factor PGD.6-8 All of them involved couples 
at risk for one genetic disease only (cystic fibrosis, 
Von Hippel-Lindau syndrome, Lynch syndrome), 
but aneuploidy screening was performed to improve 
the implantation and pregnancy rates in those of 
advanced maternal age. Our patient was at risk for 
two genetic diseases, namely alpha-thalassaemia 
and reciprocal translocation. In the aforementioned 
case reports too, two cells were removed for PGD 
(either one polar body and one blastomere, or two 
blastomeres). Although we also had two blastomeres 
biopsied in the treatment cycle of our couple, 
we have validated a protocol with which double-
factor PGD can be performed with one-blastomere 
biopsy. With the use of aCGH, it becomes feasible 
and practicable to use one blastomere for both the 
monogenetic disease diagnosis and aCGH for either 
translocation carriers or aneuploidy screening in 
at-risk couples. The turnaround time of our protocol 
was approximately 2 days, rendering the fresh cycle 
day-5 blastocyst feasible for transfer. 
Conclusion
We report the first live birth after double-factor PGD 
for alpha-thalassaemia and reciprocal translocation. 
We have also validated a protocol for double-factor 
PGD, in which WGA DNA obtained from a single 
blastomere can be used for PCR-based PGD and 
aCGH. 
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